Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROVANA vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily metabolized via glucuronidation (UGT1A1, UGT1A3, UGT1A9) and to a lesser extent by O-demethylation via CYP2D6 and CYP2E1.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 75% bound primarily to albumin and alpha-1-acid glycoprotein.
65% bound to albumin
Approximately 1.9 L/kg (indicating extensive extravascular distribution).
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Inhalation: approximately 9–15% (due to lung deposition and local metabolism; oral bioavailability <2% due to first-pass effect).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min; use with caution.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Not approved for pediatric use; safety and efficacy not established for patients <18 years.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
No specific dose adjustment; monitor for adverse effects; start at low end of dosing range if renal or hepatic impairment present.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
LABAs increase the risk of asthma-related death. BROVANA is not indicated for the treatment of asthma.
No FDA black box warning.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, QT prolongation), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and use with other beta-agonists.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to arformoterol or any component of the product, or to racemic formoterol.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
No specific food interactions. Avoid caffeine or other stimulants as they may increase sympathetic side effects (e.g., tremor, tachycardia).
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (including omphalocele and skeletal abnormalities) at doses approximately 2.4 times the maximum recommended human daily inhalation dose (MRHDID) in rats, and delayed ossification at doses approximately 0.24 times MRHDID in rabbits. Use only if potential benefit justifies potential risk to fetus. First trimester: limited human data; second and third trimesters: may cause preterm labor due to beta-adrenergic receptor stimulation; monitor for uterine contractions.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
No human data on presence in breast milk, effects on breastfed infant, or milk production. Arformoterol is excreted in rat milk at concentrations similar to maternal plasma. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need for BROVANA. M/P ratio not available.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No specific dose adjustments established. Pharmacokinetic changes in pregnancy may include increased clearance (e.g., due to increased renal blood flow and metabolic enzyme induction), but no data for arformoterol. Use lowest effective dose; monitor for efficacy and adverse effects. Dose adjustments should be individualized.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Arformoterol (BROVANA) is a long-acting beta-2 agonist (LABA) indicated for maintenance treatment of COPD, not for acute exacerbations. It should not be used with other LABAs. Monitor for paradoxical bronchospasm and cardiovascular effects. Twice-daily dosing, not once-daily like some LABAs.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Use BROVANA exactly as prescribed, twice daily (morning and evening), not for sudden breathing problems.,Do not use more than the prescribed dose; overuse can increase risk of side effects.,Rinse mouth with water after each dose to reduce risk of thrush (if using via nebulizer with a mouthpiece).,Contact your healthcare provider if symptoms worsen or you need your rescue inhaler more often.,Common side effects include headache, chest pain, back pain, diarrhea, and sinusitis.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROVANA vs AEROLATE, answered by our medical review team.
BROVANA is a Bronchodilator that works by BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROVANA and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROVANA is: 15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROVANA and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROVANA is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (inclu. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.